Abstract Library

Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.

Participants of the ENETS Conference in 2022 can now access the abstract booklet, e-posters and videos, the poster carousel, and more via My ENETS.

ENETS Abstract Search

#2269 Can Insulin-Like Growth Factor 1 (IGF-1), IGF-1 Receptor, Connective Tissue Growth Factor and Ki-67 Labelling Index Have a Prognostic Role in Pulmonary Carcinoids?

Introduction: Altered expression of Insulin-like Growth Factor-1 (IGF-1), its receptor (IGF-1R), Connective Tissue Growth Factor (CTGF) and Hypoxia Factor-1 (HIF-1), has been implicated in tumorigenesis. These factors have not been studied systematically in Pulmonary Carcinoids (PCs).

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Tsolakis A, Kanakis G, Grimelius G, Papaioannou D, Kaltsas G,

Keywords: IGF-1, IGF-1R, CTGF, HIF-1, Ki-67,

#911 Immunohistochemical Expression of Connective Tissue Growth Factor and Insulin-like Growth Factor-1 in Lung Carcinoids

Introduction: Several studies have shown altered expression of Insulin-like Growth Factor-1 (IGF-1) and its receptor (IGF-1R) in different types of cancers. Connective Tissue Growth Factor (CTGF) is triggered by Serotonin (5-HT) and Hypoxia Induced Factor 1 (HIF-1) and has been associated with tumor expansion and desmoplastic reaction in carcinoid tumors.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author:

Authors: Kanakis G, Grimelius L, Kaltsas G, Tsolakis A,

Keywords: lung, carcinoid, CTGF, IGF-1,

#819 Immunohistochemical and Genomic Evidence for the Expression of Somatostatin Receptors 1-5 and Dopamine Receptor 2 in Lung Carcinoids

Introduction: Expression of somatostatin receptors (SSTRs) and dopamine receptor 2 (DR2) in neuroendocrine tumors is of clinical importance, as they represent potential targets for diagnosis and treatment.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author:

Authors: Kanakis G, Grimelius L, Spathis A, Tringidou R, Rassidakis G,

Keywords: lung, carcinoid, somatostatin ,

#245 Expression of Somatostatin Receptors and Dopamine 2 Receptor in Lung Carcinoids as a Possible Biotherapy Target

Introduction: Expression of somatostatin receptors (SSTRs) and dopamine 2 receptor (D2R) in neuroendocrine tumors is of clinical importance, as somatostatin analogues and dopamine agonists are used in biotherapy.

Conference: 8th Annual ENETSConcerence (2011)

Presenting Author:

Authors: Kanakis G, Grimelius L, Trigidou R, Kaltsas G, Tsolakis A,

Keywords: somatostatin receptor subtypes, dopamine receptor 2, lung carcinoids,

#114 Downstaging of a gastroenteropancreatic neuroendocrine tumor after combination therapy of temozolomide, Bevacizumab and long-acting somatostatin analogs

Introduction: Patients with gastroenteropancreatic endocrine (GEP) tumors and progressive disease have been treated with several chemotherapeutic regimens with variable responses and considerable toxicity. Recent studies have shown that GEP tumors may respond to therapy with anti-angiogenic agents, mainly as a result of their increased vascularity.

Conference: 7th Annual ENETSConcerence (2010)

Presenting Author: KALTSAS G

Authors: Antoniou S, Kanakis G, Zilos A, Thomas D, Tzavaris N,

Keywords: GEPNETs, temozolomide, bevacizumab, somatostatin analogue,

Abstract Submissions in 2023

Abstract submissions for 2023 will open in September 2022!

 

The 20th Annual ENETS Conference in 2023 will provide the principal platform for NET researchers around the world to present their latest findings. ENETS will select the best abstracts submitted in both clinical and basic science and present these in sessions within the framework of its scientific programme.

 

Participants of the ENETS Conferences in 2022 can now access the abstract booklet, e-posters and videos, the poster carousel, and more via My ENETS.

Membership matters

Multidisciplinary is our credo. We welcome all NET-related disciplines and professionals! Learn more about the benefits of becoming an ENETS member.